Korea’s Celltrion, Partner Hospira Win Drug Procurement Bid In Norway For Infliximab Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Celltrion’s biosimilar infliximab has won over J&J’s Remicade in Norway’s national drug procurement bidding, and will be priced at a 39% discount to the originator product.